JP2003501344A5 - - Google Patents

Download PDF

Info

Publication number
JP2003501344A5
JP2003501344A5 JP2000585197A JP2000585197A JP2003501344A5 JP 2003501344 A5 JP2003501344 A5 JP 2003501344A5 JP 2000585197 A JP2000585197 A JP 2000585197A JP 2000585197 A JP2000585197 A JP 2000585197A JP 2003501344 A5 JP2003501344 A5 JP 2003501344A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
venlafaxine
stereoisomer
substantially free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000585197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501344A (ja
Filing date
Publication date
Priority claimed from US09/450,691 external-priority patent/US6197828B1/en
Application filed filed Critical
Publication of JP2003501344A publication Critical patent/JP2003501344A/ja
Publication of JP2003501344A5 publication Critical patent/JP2003501344A5/ja
Pending legal-status Critical Current

Links

JP2000585197A 1998-12-01 1999-12-01 （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法 Pending JP2003501344A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11048698P 1998-12-01 1998-12-01
US60/110,486 1998-12-01
US09/450,691 1999-11-30
US09/450,691 US6197828B1 (en) 1998-12-01 1999-11-30 Derivatives of (+)-venlafaxine and methods of preparing and using the same
PCT/US1999/028306 WO2000032555A1 (en) 1998-12-01 1999-12-01 Derivatives of (+)-venlafaxine and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
JP2003501344A JP2003501344A (ja) 2003-01-14
JP2003501344A5 true JP2003501344A5 (enExample) 2007-01-25

Family

ID=26808067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000585197A Pending JP2003501344A (ja) 1998-12-01 1999-12-01 （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法

Country Status (5)

Country Link
US (1) US6197828B1 (enExample)
EP (1) EP1135358A1 (enExample)
JP (1) JP2003501344A (enExample)
CA (1) CA2352321A1 (enExample)
WO (1) WO2000032555A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
WO2000076956A2 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of n-desmethyl venlafaxine
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US20020035158A1 (en) * 1999-06-15 2002-03-21 American Home Products Corporation Enantiomers of N-desmethyl venlafaxine
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
US6348494B1 (en) 2000-11-21 2002-02-19 American Home Products Corporation Ethers of o-desmethyl venlafaxine
EA200200948A1 (ru) * 2000-03-07 2003-02-27 Эли Лилли Энд Компани Лечение псориаза
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US20100196466A1 (en) * 2000-06-06 2010-08-05 Capricorn Pharma Inc. Drug delivery system
US20070059367A1 (en) * 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
TWI228118B (en) * 2000-08-30 2005-02-21 Ciba Sc Holding Ag Process for the preparation of substituted phenylacetonitriles
HRP20030392A2 (en) * 2000-10-19 2005-04-30 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphsof venlafaxine hydrochloride, processes for preparing thereof
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
EP1864967A1 (en) * 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
AU2003226751A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
MXPA04012347A (es) * 2002-06-10 2005-02-25 Wyeth Corp Nueva sal formiato de o-desmetilvenlafaxina.
CN1232501C (zh) * 2002-11-29 2005-12-21 重庆凯林制药有限公司 用于制备万拉法新中间体的环己醇衍生物的制备工艺
EP1595535A2 (en) * 2002-12-23 2005-11-16 Osmotica Costa Rica Sociedad Anonima Delivery device containing venlafaxine and memantine and use method thereof
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
KR20060132891A (ko) * 2004-02-06 2006-12-22 와이어쓰 다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
EP1904046A4 (en) * 2005-07-06 2008-10-01 Sepracor Inc COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
PL1954669T3 (pl) * 2005-12-01 2016-01-29 Auspex Pharmaceuticals Inc Podstawione fenetyloaminy o działaniu serotoninergicznym i/lub norepinefrynergicznym
EP1973866A1 (en) 2005-12-20 2008-10-01 Synthon B.V. Process for making desvenlafaxine
MX2007016179A (es) * 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
CA2646368A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Substantially pure o-desmethylvenlafaxine and processes for preparing it
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
CN100506784C (zh) * 2006-05-22 2009-07-01 浙江苏泊尔制药有限公司 万拉法新的制备方法
WO2008013995A2 (en) * 2006-07-26 2008-01-31 Teva Pharmaceutical Industries Ltd. Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine
EP1934168A2 (en) * 2006-07-26 2008-06-25 Teva Pharmaceutical Industries Ltd Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
JP4763788B2 (ja) * 2006-07-26 2011-08-31 テバ ファーマシューティカル インダストリーズ リミティド Ｏ−デスメチルベンラファキシンの合成方法
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20100121108A1 (en) * 2006-08-04 2010-05-13 Medichem, S.A. Process for synthesizing desvenlafaxine free base and salts or solvates thereof
WO2008017886A1 (en) * 2006-08-08 2008-02-14 Generics [Uk] Limited Novel hydrate form of o-desmethyl venlafaxine succinate
WO2008112313A2 (en) * 2007-03-14 2008-09-18 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
IN2007CH01519A (enExample) * 2007-07-16 2009-09-11 Matrix Lab Ltd
EP2211847A4 (en) * 2007-10-16 2013-10-02 Alphapharm Pty Ltd PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE
WO2009053731A1 (en) 2007-10-26 2009-04-30 Generics [Uk] Limited Process for preparing o-desmethylvenlafaxine
WO2009070311A2 (en) * 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
EP2074993A1 (en) 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxine-containing film-coated modified-release tablets
WO2009084039A2 (en) * 2007-12-26 2009-07-09 Matrix Laboratories Limited Process for producing 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
US20090234020A1 (en) * 2008-03-06 2009-09-17 Valarie Niddam-Hildesheim Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities
KR100965527B1 (ko) 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
US20110112200A1 (en) * 2008-06-16 2011-05-12 Valerie Niddam-Hildesheim Solid states of o-desmethylvenlafaxine salts
EP2364151A1 (en) * 2008-10-30 2011-09-14 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
US20110184067A1 (en) * 2010-01-25 2011-07-28 Intas Pharmaceuticals Ltd. O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
US8569371B2 (en) * 2010-03-29 2013-10-29 Pliva Hrvatska D.O.O. Crystal forms of O-desmethylvenlafaxine fumarate
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
CZ303249B6 (cs) 2010-04-06 2012-06-20 Zentiva, K.S. Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
US8933123B2 (en) 2010-10-08 2015-01-13 Cadila Healthcare Limited Polymorphic forms of O-desmethyl-venlafaxine succinate
BR112013025766A2 (pt) 2011-04-12 2016-12-20 Lupin Ltd composições farmacêuticas de liberação modificada de desvenlafaxina
CN104529797A (zh) * 2014-12-05 2015-04-22 南昌市博泽康医药科技有限公司 盐酸文拉法辛手性晶型的制备
MX367362B (es) 2016-06-29 2019-08-16 Alparis Sa De Cv Nuevas formas solidas de desvenlafaxina.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56324B1 (en) 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
JPH08500093A (ja) 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
AU4542993A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression

Similar Documents

Publication Publication Date Title
JP2003501344A5 (enExample)
JP2003524613A5 (enExample)
JP2003521470A5 (enExample)
CA2352324A1 (en) Derivatives of (-)-venlafaxine and methods of preparing and using the same
AU782092B2 (en) Derivatives of venlafaxine and methods of preparing and using the same
KR100720290B1 (ko) 부프로피온 대사물, 이들의 합성방법 및 사용방법
US6197828B1 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
CA2341441A1 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
JP2002523366A5 (enExample)
CN1980667A (zh) 治疗、预防或控制不良睡眠和不良睡眠相关疾病的方法和组合物
JP2002515435A (ja) 鬱病処置のための組合せ治療
US20130296414A1 (en) 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence
JP2016539994A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
MXPA05000791A (es) Compuestos de 1-fenil-2-dimetilaminometil ciclohexano para la terapia de sintomas depresivos, dolor e incontinencia.
JP2015510893A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
JP2005531594A (ja) 慢性苦痛の治療用トリプルモノアミン再取り込み阻害剤
JP2005531594A5 (ja) 慢性痛の治療用トリプルモノアミン再取り込み阻害剤
JP2019529502A5 (enExample)
KR20190087573A (ko) 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP2004523495A (ja) ヒドロキシル化シクロブチルアルキルアミンの合成、使用法および組成物
TW202541802A (zh) 神經退化性疾病治療劑
RU2004116282A (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
JPH02221222A (ja) モノアミンオキシダーゼ阻害剤
JP2001233762A (ja) Ｏ−デスメチル−ｎ−モノ−デスメチル−トラマドールの使用方法
MXPA06007165A (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases